


REVIEW

Open Access



Vaccines as alternatives to antibiotics for food producing animals. Part 2: new approaches and potential solutions

Karin Hoelzer^{1*} , Lisa Bielke², Damer P. Blake³, Eric Cox⁴, Simon M. Cutting⁵, Bert Devriendt⁴, Elisabeth Erlacher-Vindel⁶, Evy Goossens⁷, Kemal Karaca⁸, Stephane Lemiere⁹, Martin Metzner¹⁰, Margot Raicek⁶, Miquel Collell Suriñach¹¹, Nora M. Wong¹, Cyril Gay¹² and Filip Van Immerseel⁷

Abstract

Vaccines and other alternative products are central to the future success of animal agriculture because they can help minimize the need for antibiotics by preventing and controlling infectious diseases in animal populations. To assess scientific advancements related to alternatives to antibiotics and provide actionable strategies to support their development, the United States Department of Agriculture, with support from the World Organisation for Animal Health, organized the second International Symposium on Alternatives to Antibiotics. It focused on six key areas: vaccines; microbial-derived products; non-nutritive phytochemicals; immune-related products; chemicals, enzymes, and innovative drugs; and regulatory pathways to enable the development and licensure of alternatives to antibiotics. This article, the second part in a two-part series, highlights new approaches and potential solutions for the development of vaccines as alternatives to antibiotics in food producing animals; opportunities, challenges and needs for the development of such vaccines are discussed in the first part of this series. As discussed in part 1 of this manuscript, many current vaccines fall short of ideal vaccines in one or more respects. Promising breakthroughs to overcome these limitations include new biotechnology techniques, new oral vaccine approaches, novel adjuvants, new delivery strategies based on bacterial spores, and live recombinant vectors; they also include new vaccination strategies in-ovo, and strategies that simultaneously protect against multiple pathogens. However, translating this research into commercial vaccines that effectively reduce the need for antibiotics will require close collaboration among stakeholders, for instance through public–private partnerships. Targeted research and development investments and concerted efforts by all affected are needed to realize the potential of vaccines to improve animal health, safeguard agricultural productivity, and reduce antibiotic consumption and resulting resistance risks.

Table of Contents

1 Introduction

2 New approaches for the development of veterinary vaccines

2.1 Mucosal immunity and tolerance: challenges to the development of effective oral vaccines

2.2 Recombinant *Bacillus* spores as oral vectored vaccines

2.3 Genetically modified live microorganisms as oral vectored vaccines and vaccine platforms

2.4 New approaches for in-ovo vaccines

3 Vaccination strategies to reduce antibiotic use for diseases from ubiquitous pathogens

3.1 Towards the development of new *Clostridium perfringens* vaccines

3.2 Towards the development of new coccidiosis vaccines 3.2.1 Management of coccidiosis through anticoccidial drugs

3.2.2 Traditional live anticoccidial vaccines

*Correspondence: khoelzer@pewtrusts.org

¹ The Pew Charitable Trusts, 901 E Street NW, Washington, DC 20004, USA
Full list of author information is available at the end of the article



3.2.3 Next generation anticoccidial vaccines

4 Autogenous vaccines to reduce the need for antibiotic use

5 Conclusions

References

1 Introduction

Alternatives to antibiotics can help minimize the need for antibiotics by helping to prevent and control infectious diseases in animal populations. As such, safe and effective alternatives are crucially important to the future success of animal health and production. To assess scientific advancements in the research and development of alternatives to antibiotics, highlight promising research results and novel technologies, assess challenges associated with their commercialization and use, and provide actionable strategies to support their development, the United States Department of Agriculture (USDA), with support from the World Organisation for Animal Health (OIE), organized the second International Symposium on Alternatives to Antibiotics. The symposium focused on six key areas: vaccines; microbial-derived products; non-nutritive phytochemicals; immune-related products; chemicals, enzymes, and innovative drugs; and regulatory pathways to enable the licensure and development of alternatives to antibiotics. This two-part manuscript synthesizes and expands on the scientific presentations and expert panel discussions from the symposium regarding the use of vaccines as alternatives to antibiotics that can reduce the need for antibiotic use in animals. Part 1 synthesizes and expands on the expert panel discussions regarding the opportunities, challenges and needs related to vaccines that may reduce the requirement for use of antibiotics in animals, while part two focuses on highlighting new approaches and potential solutions.

A general discussion of the importance of antibiotic resistance and the opportunities, challenges and needs related to vaccines as alternatives that may reduce the need for use of antibiotics in animals is provided in part 1 of this review, including a discussion of the properties of ideal vaccines, how current vaccines compare to these ideal vaccines, and how investment decisions around research and development of vaccines are made. This second part of the manuscript will highlight specific research advancements in the area of veterinary vaccines.

2 New approaches for the development of veterinary vaccines

2.1 Mucosal immunity and tolerance: challenges to the development of effective oral vaccines

As mentioned in part one of this manuscript, most pathogens invade the host at the mucosal surfaces, such as the gastro-intestinal (GI) tract. The GI tract constitutes

the largest surface area of the body and is exposed daily to vast numbers of foreign antigens derived from feed, the microbiota and pathogens [1]. Within the intestine a complex cellular network has evolved to prevent unwanted immune responses to innocuous antigens, for instance feed or microbiota, while allowing swift protective responses against agents that cause infectious disease. Key to keeping enteric pathogens at bay is the presence of protective pathogen-specific secretory IgA (SIgA) at the site of entry, which prevents the adhesion of micro-organisms to the intestinal surfaces and neutralizes their enterotoxins. Triggering robust and protective intestinal SIgA responses usually requires the local administration of vaccines [2]. Although live attenuated oral vaccines have had tremendous success, resulting for instance in the near global eradication of poliovirus [3], concerns on the dissemination of vaccine strains into the environment and rare cases of reversion to virulence, leading to vaccine-induced disease, have driven oral vaccine development to nonliving or vectored vaccines [4]. However, oral vaccination is challenging due to several hurdles imposed by the cellular and molecular architecture of the gut: (i) the harsh environment of the stomach and small intestine, including the low pH, digestive enzymes, and bile salts, required to digest feed also easily destroys vaccines, (ii) a poor uptake of vaccine antigens by the intestinal epithelial barrier and (iii) the tolerogenic mechanisms that pervade the intestinal tissues, leading to peripheral and oral immune tolerance upon oral administration of antigens via the induction of FoxP3⁺ regulatory T cells. This often results in a low immunogenicity of oral vaccines and requires innovative strategies to deliver the vaccine antigens to the intestinal immune system as well as the inclusion of adjuvants that promote innate and adaptive immunity [5].

The mucosal immune system in the gut can be divided in inductive sites, where sampled antigens stimulate naive T and B cells, and effector sites, where effector cells perform their functions, e.g. assisting in the production of SIgA. In the small intestine, the inductive sites comprise the gut-associated lymphoid tissues (GALT) and the mesenteric lymph nodes, while the effector sites constitute the lamina propria and the surface epithelium [6]. The GALT itself is composed of Peyer's patches (PP), appendix and isolated lymphoid follicles. The presence of other GALT-like structures, such as lymphocyte-filled villi (rat, human) and cryptopatches (mouse) is dependent on the species. Interestingly, while in birds and most mammals PP or their equivalent are scattered throughout the small intestine, in pigs, ruminants and dogs the PP in the distal small intestine (ileum) are continuous. Fish and reptiles on the other hand lack PP and the intestinal immune system in these species is composed of epithelial leukocytes

and rare, small non-organized lymphoid aggregates. It remains largely unknown how these species-specific differences might affect the efficacy of oral vaccines.

From their entry point, which is typically the oral cavity, to their delivery site, most commonly the small intestine, the integrity of delivery systems and the stability of vaccine components are at risk. Lysozyme in saliva, the low gastric pH together with pepsin and intestinal proteases can degrade oral vaccines. Enteric coating of vaccine components with pH-responsive polymers with a dissolution threshold of pH 6 might protect against gastric degradation and results in the release of their contents in the small intestine [7]. In this context, ruminants pose an additional problem to vaccine stability as their polygastric gastro-intestinal tract effectively degrades substances including vaccines. Site-specific delivery of oral vaccines to the small intestine is favorable as the mucus layer covering the small intestinal epithelium consists of only one layer, which is loosely adherent, less thick and patchy as compared to the colonic mucus layers and might promote their access to the intestinal epithelium. In addition, the small intestine is less densely populated by the microbiota, which might further disrupt the integrity of the delivery systems and the stability of vaccine components. Underneath the mucus layer, a single layer of intestinal epithelial cells prevents uncontrolled access of the luminal content to the underlying intestinal tissues, further restricting uptake of oral vaccine antigens. Crossing of the epithelial barrier by vaccines could be enhanced by exploiting antigen sampling routes in the small intestine or by adopting strategies used by enteric pathogens to colonize or invade the host [8]. The best-known sampling route in the gut is associated with microfold (M) cells. These specialized intestinal epithelial cells reside within the follicle-associated epithelium covering the Peyer's patches and take up macromolecules, particulate matter and microorganisms [9]. Many enteric pathogens hijack M cells to invade the host by binding to apical receptors. For instance, the invasive protein of *Yersinia* species interacts with $\beta 1$ integrin on M cells, leading to infection [10]. Likewise, GP2 marks M cells in many species and binds to FimH, a subunit of type I pili on *Escherichia coli* and *Salmonella enterica*. This interaction results in uptake of FimH⁺ bacteria and initiates mucosal immunity [11]. Although many groups have focused on improving antigen uptake by targeting oral vaccines to M cell-specific receptors, these cells represent only a small, species-specific percentage of the total intestinal epithelial cell population. Although M cell numbers increase from the cranial to caudal small intestine and M cell targeting strategies work quite well in rodent models, they mostly fail in larger animals due to the long passage time needed to reach the distal small intestine,

where the gut-associated immune system is most pronounced. Besides M cells, sampling of luminal antigens also occurs by intestinal mononuclear phagocytes via transepithelial dendrites. This sampling mainly occurs by CD11c⁺CX3CR1⁺ macrophages, which transfer the antigens to CD103⁺ dendritic cells (DCs). These DCs then drive the differentiation of regulatory T cells (Tregs), which subsequently induce tolerance to these proteins [12]. In the steady state, goblet cells can also transport small soluble proteins (<10 kDa) across the epithelium to tolerogenic DCs via so-called goblet cell-associated antigen passages [13]. Absorptive intestinal epithelial cells or enterocytes, constituting >90% of the small intestinal epithelium, may also sample the luminal content through receptor-mediated transcytosis. For instance, the neonatal Fc receptor (FcRn), an MHC class I-like Fc γ receptor, is expressed on the apical surface of enterocytes and transcytoses IgG, immune complexes or Fc-coated nanoparticles from the lumen to the basolateral surface of the epithelium [14]. Similar to M cells, it might be worthwhile to target apical receptors exploited by enteropathogens on small intestinal enterocytes to promote uptake of antigens by the epithelial barrier. A potential candidate would be aminopeptidase N (ANPEP), a zinc-dependent peptidase present in the brush border of small intestinal enterocytes, which serves as an entry receptor for several coronaviruses and also binds F4 fimbriae, a colonisation factor produced by porcine-specific enterotoxigenic *E. coli*. ANPEP also transports F4 fimbriae as well as micro-particles functionalised with ANPEP-specific monoclonal antibodies across the intestinal epithelial barrier, resulting in robust intestinal SIgA responses, at least in piglets [15, 16].

Although the selective targeting of vaccine antigens to apical receptors might promote their uptake by the epithelium via transcytosis, this process is in itself insufficient to trigger protective intestinal immunity upon oral vaccination and explains the need to include adjuvants. These adjuvants should act on antigen presenting cells as well as intestinal epithelial cells to promote the induction of protective SIgA and cell-mediated immune responses. Indeed, enterocytes not only provide a physical barrier separating the intestinal lumen from the host tissues, but also relay information on the luminal content to the underlying immune cells through the secretion of inflammatory or tolerogenic mediators. For instance, during the steady state, enterocytes produce thymic stromal lymphopoietin (TSLP) and transforming growth factor (TGF β), which imprint a tolerogenic phenotype on intestinal dendritic cells [17]. In contrast, upon infection enterocytes secrete IL-6 and IL-8 [18]. This probably facilitates a switch from a tolerogenic to an immune-inductive environment, allowing activation

of intestinal antigen presenting cells. As yet the most effective adjuvants for oral application are the enterotoxins from *Vibrio cholera* (CT) and enterotoxigenic *E. coli* (ETEC) (LT). Due to inherent toxicity, dmLT was developed, a nontoxic LT mutant retaining its adjuvanticity. This dmLT triggered intestinal memory responses upon oral vaccination with a nonliving ETEC vaccine and seems a promising candidate to be included as adjuvant in oral vaccines [19, 20]. Similarly promising strategies have been reported for *Eimeria* [21]. Recent studies have shown that *Eimeria*-induced IL-17 production is critical in the initiation of early innate immune response in coccidiosis and blocking of IL-17 production by exogenous IL-17-neutralizing antibody reduced both the intracellular development of *Eimeria* and the severity of intestinal lesion [22–24].

In summarizing this part, future design of oral vaccines should be tailored to the needs of the target species, focus on the selective delivery of vaccines to epithelial receptors to promote their transport across the epithelial barrier, induce protective immune response in the target tissues, and should include a mucosal adjuvant able to trigger memory SIgA responses.

2.2 Recombinant *Bacillus* spores as oral vectored vaccines

Endospores, or spores, are produced by many bacteria as a response to nutrient deprivation. The spore is a dormant entity about 1 μm in size that can germinate, allowing a nascent cell to emerge and enter vegetative cell growth [25]. The spore carries remarkable resistance properties, being typically resistant to high temperatures (typically 70–80 °C), desiccation, irradiation, and exposure to noxious chemicals [26]. The two principal spore-forming bacterial genera are *Bacillus* and *Clostridia* with the latter being exclusively anaerobic.

Members of the *Bacillus* genus are being used as probiotics, that is, microorganisms that are added to the diet to improve the balance of microbial communities in the GI-tract and are therefore beneficial to human or animal health [27, 28]. Typical species include *Bacillus clausii*, *Bacillus coagulans* and *Bacillus subtilis*. For a long time, it has been assumed that *Bacillus* spores are soil organisms yet the evidence supporting this is actually rather sparse. Instead, spores are found in the soil in abundance but live, vegetative cells, are rarely if ever found other than in association with plants or in the animal gut. Mounting evidence shows that spores, although found in the soil, are mostly dormant and are shed in the feces of animals, which are their natural hosts [29]. The consumption of spores associated with soil-contaminated plant matter enables spores to enter the GI-tract, transit the gastric barrier unscathed and then germinate and proliferate in the intestine before excretion as dormant spores [30].

Evidence suggests that spore forming bacteria comprise as much as 30% of the gut microbiota, indicating that the ability to form spores enables bacteria to survive in the environment as well as entering and transiting the gastric barrier of animals [31].

The extraordinary resistance properties of *Bacillus* spores coupled with their ease of genetic manipulation, and their successful use as probiotics, makes them attractive candidates for the delivery of heterologous antigens for vaccination. Spores have been used as vaccine vehicles in a number of ways, differing principally in whether spores are genetically modified or not. In all cases *B. subtilis* has been utilized due to the excellent genetics available. Using genetic modification, a chimeric gene consisting of a fusion between a *B. subtilis* anchor gene and an open reading frame encoding a putative protective antigen is first constructed. The next step is introduction of the chimera into the *B. subtilis* chromosome using a gene transfer technique, typically DNA-mediated transformation, a process in *B. subtilis* that is straightforward. Typically, the anchor is the 5'-end of a gene encoding a spore coat protein such that the chimera is displayed on the spore coat. Surprisingly, heterologous antigens displayed on *B. subtilis* spores are mostly stable and do not appear to suffer extensive degradation. Using this approach a number of candidate antigens have been displayed and then evaluated in animal models. For example, spores displaying a tetanus antigen TTFC conferred protection to a lethal dose of tetanus toxin when administered orally [32, 33]. Mice dosed orally with spores expressing part of the alpha toxin of *Clostridium perfringens* were protected to challenge with alpha toxin [34]. A more recent example is that of *Clostridium difficile* where a C-terminal fragment of the toxin A (TcdA) could be stably expressed and when administered orally to hamsters conferred protection to *C. difficile* infection [35, 36]. This particular vaccine has now entered clinical evaluation in humans [37].

Using a non-genetically modified organism (GMO) approach it has been shown that spores can adsorb antigens efficiently onto their surface and surprisingly this is both strong and stable, and reflects the unique biophysical properties of the spore [38]. For the adsorption approach, it has been shown that the gastric barrier is particularly corrosive and adsorbed antigens are labile, but for intranasal delivery this method appears satisfactory. Using this approach inactive (killed) spores can be used and success has included studies showing protection to influenza (H5N1) [39] and significant reduction in lung counts of animals challenged with *Mycobacterium tuberculosis* [40]. A unique feature of spores is their ability to enhance immune responses and this adjuvant effect has been characterized in depth [41–43].

However, the use of spores as mass-delivery vehicles for vaccines has several limitations. Oral delivery clearly is the preferred approach but appears to work effectively only for the GMO approach. Oral delivery also raises issues of tolerance and may prove to be a limiting factor. Sublingual delivery has also been explored; this approach appears to provide levels of protection that are equivalent to oral delivery, but requires more doses [36, 44]. Nasal delivery is suitable but raises potential safety issues. For animal vaccines, spores are attractive since they are currently used as feed probiotics but also because they can survive the high temperatures used for feed production and may offer long-term utility. As mentioned already, spores have been manipulated for protection against *C. perfringens* but there now exists the opportunity to develop spores for protective vaccination to necrotic enteritis, an important poultry disease caused by *C. perfringens* that has been identified as a high vaccine research priority by the OIE *ad hoc* Group (see Additional file 2 in <http://doi.org/10.1186/s13567-018-0560-8>).

One application that is particularly promising is the use of spore vaccines in aquaculture. With intensive fish farming, *Bacillus* spores are being used as probiotic feed supplements. For shrimp farming, viral diseases have devastated the industry and one of the most important shrimp pathogens is white spot syndrome virus (WSSV) that causes seasonal outbreaks of disease [45]. A number of groups have developed *B. subtilis* spores that display the VP28 capsid protein of WSSV and when administered in feed appears to protect against white spot disease [46–49]. The mechanism for protection is intriguing; even though shrimp are not thought to produce antibodies, it is clear that presentation of the viral antigens does produce some level of specific immunity.

Despite the progress being made with spore vaccines one key issue remains: the containment of GMOs. Because spores are dormant with the potential to survive indefinitely in the environment, the use of recombinant spores in spore vaccines is likely to raise environmental concerns and successful regulatory approvals may be slow or impossible to secure. For human use, it is likely that a case can be made that the recombinant spore vaccines addresses an unmet clinical need, but for animal use devising a method for biological containment will be crucial.

2.3 Genetically modified live microorganisms as oral vectored vaccines and vaccine platforms

Technological advancements now make it possible to genetically engineer bacteria and other microorganisms that deliver heterologous antigens in a way that can stimulate mucosal as well as humoral and cellular systemic

immunity [50]. Multiple species of bacteria including *Salmonella* Typhimurium, *Salmonella* Enteritidis, *Salmonella* Typhi, *E. coli*, *Lactococcus lactis*, *Lactobacillus casei*, *Lactobacillus reuteri*, *Bacillus subtilis*, and *Bacillus thuringiensis*, have been used to express protein antigens derived from bacterial, viral, and protozoal pathogens [51–61]. Some of these vectors are inherently non-pathogenic; *Lactobacillus* and *Lactococcus* strains, for instance, are “Generally Recognized as Safe” (GRAS) [50, 61]. In other cases the microorganisms have been rendered non-pathogenic through the targeted deletion of virulence genes; strategies for the development of *Salmonella* vectors, for instance, typically rely on the deletion of certain metabolic functions that limit the bacterium’s ability to replicate in the host and attenuate virulence without impacting host colonization or invasion [50]. In fact, an intrinsic property shared by many, although not all, microorganisms used as vectors is their ability to effectively infect the host and initiate innate and subsequent adaptive immune responses, for instance by triggering the host’s pattern recognition receptors [50]. These recombinant vectored vaccines can be delivered directly to a mucosal surface via nasal, ocular, or oral administration, which not only allows for mass application but may also enhance mucosal immune responses, the primary surface through which most pathogens invade. Moreover, contrary to traditional attenuated live vaccines, these recombinant vaccines in many cases do not carry a risk of reversion [50].

In veterinary medicine, oral vectored vaccines have been instrumental in the eradication or control of rabies in wildlife reservoirs [62, 63]. Oral vectored vaccines have also been developed for several other veterinary applications, including some economically important diseases of food-producing animals that are associated with considerable antibiotic use such as porcine circovirus type-2 (PCV-2); in some cases, the vaccine vector is a chimera containing parts of multiple microorganisms—for instance, an attenuated live vaccine may be used as the vector—and the resulting vaccine simultaneously confers protection against multiple diseases, for instance Marek’s disease and infectious bursal disease or Newcastle disease and avian influenza [63, 64].

The development of some vaccine vector systems has been very successful and numerous veterinary vaccines have been developed based on them; the canarypox virus vector system ALVAC, for instance, has been used for the development of a range of veterinary vaccines including against rabies, influenza, and West Nile virus [64]. Similarly, adenovirus vectors have also been widely used in veterinary medicine, both in companion and food-producing animals [65]. Vaccine platforms such as these are particularly valuable as they can allow for the

rapid development of vaccine candidates in response to emerging vaccine needs, but the possibility of anti-vector immunity can restrict their usefulness [66]. Research and development of additional vaccine vector platforms is therefore needed. *Salmonella* strains that express foreign antigens, either chromosomally or plasmid-based, have yielded promising results in several species including mice, humans, pigs and chicken [67–72]. Diseases for which these *Salmonella* vectored vaccines were investigated include influenza, *Brucella abortus*, post-weaning diarrhea and heterologous strains of *Salmonella* [69–72]. The use of *Pasteurellaceae* as vectors for modified live vaccines against shipping fever in calves is currently under investigation, with promising preliminary findings [73]. Use of this vector system for other diseases including pinkeye has been suggested [73].

2.4 New approaches for in-ovo vaccines

In-ovo vaccination is a mass-vaccination strategy that is mainly used in broiler chickens albeit occasionally also in broiler-breeder and layer chickens [74]. Eggs are injected in the hatchery, typically during the third week of embryonic development around day 18 or 19. To vaccinate, a small hole is made in the shell at the blunt end of the egg and the vaccine is injected below the chorion-allantoic membrane into the amniotic cavity or directly into the embryo. Commercial in-ovo vaccination systems that automatically inject the eggs have been available since the early 1990s. More than 90% of broiler chickens in the US are vaccinated in ovo, and in Brazil that fraction equals 70% [75]. The most common use of in-ovo vaccination is for Marek's disease, potentially combined with vaccines against other diseases such as Gumboro or Newcastle disease.

The ability to deliver a clearly defined vaccine dosage to every single chick and to invoke early protection in the chicks is among the main benefits of this technology, but it is labor-intensive, causes stress for the chicks, and high sanitary standards need to be followed during vaccine preparation and injection to manage infection risks [74, 76]. In addition, the location of the vaccine injection is critical for efficacy. It has been shown, for instance, that if Marek's disease vaccine is accidentally deposited into the air cell or allantoic fluid, adequate protection is not achieved [77]. The stage of embryonic development can have profound effects on vaccine safety and efficacy [78]. One study, reported that vaccination of 10–12 day-old embryos with herpes virus of turkeys (HVT) led to pronounced lesions and embryonic deaths, while vaccination on days 16 did not cause detectable lesions [78]. Embryonic age at vaccination has also been shown to be correlated with antibody titers [79]. Maternal antibody titers actually increase after the typical age for in-ovo

vaccinations and peak just after hatch [76]. This can interfere with proper vaccine responses. However, evidence suggests that some vaccine strains are more affected by maternal antibodies than others [80]. Deliberate vaccine development may therefore limit the often disruptive effects that can be caused by maternal antibodies [78]. Other factors that need to be considered in the development of a successful in-ovo vaccination program include the characteristics of the vaccine or vaccines to be used, the type of incubator in which the eggs are housed in the hatchery, and the breed and age of the parent flock [76].

In-ovo vaccination strategies are promising means of reducing antibiotic use in poultry production and have been the subject of intense research. Importantly, they can provide robust and early protection against immune suppressive diseases such as infectious bursal disease [81, 82] and vaccines against multiple diseases have been successfully combined. For instance, studies have shown that in-ovo vaccination strategies can simultaneously confer protective immunity against Marek's disease, infectious bursal disease, Newcastle disease, fowl poxvirus, coccidiosis, and necrotic enteritis [83, 84]. Other combination vaccines under investigation include vectored vaccines that simultaneously provide protection against Newcastle disease and infectious bursal disease [85]. In-ovo vaccination strategies have also been explored for other poultry diseases with promising results. This included an avian influenza vaccine based on a non-replicating human adenovirus vector [86], a recombinant viral vector vaccine against infectious laryngotracheitis [87], recombinant protein *Eimeria* vaccines [84, 88, 89] and a fowl adenovirus vectored vaccine against inclusion body hepatitis [90], among many others. A *Mycoplasma gallisepticum* vaccine for in-ovo vaccination of layer chickens has also recently been evaluated, even though high chick losses at hatch were reported for the medium and high doses of the vaccine that were investigated [91]. Therefore, in-ovo vaccination strategies are capable of controlling several economically important poultry diseases. Many of these diseases are viral, but can predispose animals to secondary bacterial infections. Therefore, in many cases, in-ovo vaccines are promising alternative approaches to the use of antibiotics.

3 Vaccination strategies to reduce antibiotic use for diseases from ubiquitous pathogens

3.1 Towards the development of new *Clostridium perfringens* vaccines

Clostridium perfringens is widespread in the environment and in the gastrointestinal tract of most mammals and birds. However, this bacterium is also one of the most common pathogens of food-producing animals, causing disease only under circumstances that create an

environment which favors growth and toxin production, such as stress, injury, or dietary changes [92]. The bacterium itself is not invasive, but causes disease through the production of a wide array of toxins and enzymes. However, no single strain produces this entire toxin repertoire, resulting in considerable variation in the toxin profiles and disease syndromes produced by different toxinotypes of this bacterium [93]. While some of these toxins act only locally, other toxins which are produced in the gut exert their action in other internal organs or can act both locally and systemically [94–96]. To date, efficacious vaccines are only available for the diseases caused by systemic action of the toxins and vaccination against enteric diseases still remains a challenge. However, some of these enteric diseases caused by *C. perfringens* are of major economic importance and lead to considerable use of antibiotics. Amongst them are necrotic enteritis in broilers and necro-haemorrhagic enteritis in calves. Despite the fact that much research is being directed to the development of novel vaccines against these *C. perfringens*-induced enteric diseases, several key barriers still have to be overcome.

In general, clostridial vaccines require multiple doses to achieve full immunity. Unfortunately, parenteral booster immunizations are impossible in the broiler industry, where mass parenteral vaccination is only feasible at the hatchery, either in ovo or on day-old chicks. Because single parenteral vaccination at day of hatch offers no protection, other delivery methods need to be developed [97]. Oral vaccines can more easily be administered to birds, without the need of individual handling of the chicks and are therefore recommended. However, some questions arise when developing an oral vaccine as compared to the parenteral administration route. In addition to the fact that maternal antibodies can block the immune response in young chicks, also the induction of oral tolerance has to be circumvented and an efficient way to present the antigens to the mucosal immune system has to be developed. Oral tolerance is a common problem in mammals and fish when developing oral vaccines. This is in contrast to chickens, where oral tolerance is age-dependent, and only an issue in 1- to 3-day-old chicks. After that age, protein antigens have been shown to induce a robust immune response and oral vaccination schemes are thought to be feasible [98]. One appealing strategy for the delivery of vaccine candidates to the mucosal immune system is the use of attenuated or avirulent bacteria as antigen vehicles [99]. Attenuated recombinant *Salmonella* strains which express *C. perfringens* antigens have been tested in several studies as oral vaccine vectors, leading to some promising results. However, the amount of protection afforded by these vaccines is not as high as compared to multiple doses of parenteral

vaccination, and seems to depend on the colonization level and persistence of the vaccine strain [100–103]. This indicates that the use of live vectors to express antigens derived from *C. perfringens* strains in the gut of broilers is a promising approach, but the vaccine delivery strategy still needs to be optimized to achieve optimal antigen presentation to the mucosal immune system and provide improved protection. Alternatives to attenuated *Salmonella* strains can be *Bacillus subtilis* spores or *Lactobacillus casei*, which both have a GRAS status and have the potential to be used as vaccine carriers for *Clostridium* antigens [34, 104]. *B. subtilis* has the advantage that the heat-stable spores can easily be incorporated in the feed and *L. casei* has known probiotic effects that facilitate the development of mucosal immunity. However, these types of vectors still have to be tested for their capacity to induce a good immune response, in particular against heterologous antigens, in broilers and whether they are able to provide protection against necrotic enteritis.

Another issue to be addressed when developing a vaccine against *C. perfringens*-induced enteric diseases is the choice of the antigens to be included in the vaccine. *C. perfringens*-induced diseases are the result of the toxins and enzymes that are produced and vaccination of chicks with *C. perfringens* supernatants provides protection against experimental necrotic enteritis [97, 105]. However, the protective capacity of the supernatants depends on the strain used for supernatant preparation, indicating that full protection might be determined by an effective combination of different bacterial immunogens [105]. In order to elucidate the optimal mixture of antigens to protect against necrotic enteritis, challenge trials are being performed mostly using parenteral vaccination schemes. Once the ideal combination of antigens is known, this will have to be adapted to oral delivery strategies. Several *C. perfringens* antigens have been evaluated as potential vaccine candidates. The tested antigens include both *C. perfringens* toxins (e.g. alpha toxin and the NetB toxin) and highly immunodominant proteins identified in post-infection serum from birds immune to necrotic enteritis [106]. In general, immunization studies of broilers with a single antigen all resulted in some level of protection against experimental necrotic enteritis. Remarkably, immunization with NetB toxin, which is essential to cause disease in broilers, does not afford higher levels of protection than vaccination with other toxins or proteins. However, when birds were vaccinated either via the parenteral or the oral route, with a combination of both NetB toxin and alpha toxin, higher levels of protection were obtained [107, 108]. In order to obtain full protection against *C. perfringens*-induced enteric diseases, not only antibodies that inhibit toxin activity might be needed; a combination of antigens targeting also bacterial

proliferation, colonization and/or nutrient acquisition could be more efficient than either one of the individual approaches. Indeed, in a recent study disruption of the putative adhesin-encoding gene *cnaA* resulted in a reduced ability to colonize the chicken intestinal mucosa and to cause necrotic enteritis [109]. This strengthens the idea that vaccine antigens that target bacterial colonization might be indispensable to obtain a working vaccine against *C. perfringens*-induced enteric diseases. Additional vaccine targets might be enzymes that aid in breakdown of the host tissue and nutrient acquisition, such as, amongst others, mucinases, collagenases and hyaluronidases.

In contrast to the extensive efforts to develop a vaccine against necrotic enteritis in chickens, considerably less research has been directed to vaccination against necro-haemorrhagic enteritis in calves. The recent demonstration of the essential role of alpha toxin in necro-haemorrhagic enteritis and the proposition of a pathogenesis model will allow for the more targeted development of a vaccine [110, 111]. In calves as in chickens, protection against *C. perfringens*-induced necrosis can be obtained by antibodies against a mixture of toxins, at least in an experimental model for bovine necro-haemorrhagic enteritis [112]. Furthermore, antibodies against alpha toxin alone, which is essential to cause intestinal disease in calves, are not sufficient to provide the same level of protection as antibodies directed against a mixture of *C. perfringens* proteins, indicating that a mixture of different antigens will be needed to provide full protection [110]. In order to fully protect calves against *C. perfringens*-induced enteric diseases, antigens that target bacterial colonization and proliferation might be of equal importance as antigens targeting the toxin activities. Next, it has to be explored whether parenteral vaccination is sufficient to induce a protective immune response or if a combination of systemic and mucosal immunity is needed when not only the bacterial toxins but also bacterial colonization is targeted.

As administration of multiple parenteral doses of a vaccine to calves is more feasible than for chicken, it may be assumed that the development of a vaccine against necro-haemorrhagic enteritis is more straightforward and that *C. perfringens* supernatants can be used as a vaccine preparation. However, native toxins cannot be used as vaccine antigens due to safety issues. Inactivation of clostridial toxins is generally achieved by formaldehyde treatment, which risks residual formaldehyde in the vaccine preparation, incomplete inactivation of the toxins, and batch-to-batch variation. Moreover, formaldehyde inactivation can induce changes in the tertiary protein structures of relevant antigens and influence the immunogenicity of the vaccines. Indeed, vaccination of

both chickens and calves with formaldehyde inactivated *C. perfringens* supernatants or toxins have resulted in a good antibody response, but these are unable to protect against intestinal disease [97, 112]. To overcome the need of chemically inactivating the *C. perfringens* toxins, current research focusses on the use of recombinant toxoids to develop a vaccine against *C. perfringens*-induced diseases. While this may be a good strategy to obtain a safe and protective vaccine on a laboratory scale, the production process is more laborious and time-consuming than production of conventional toxoids, especially because of the required purification steps [113]. Therefore, recent studies have explored the use of efficient low-cost alternatives, such as non-purified recombinant clostridial toxins and even recombinant bacterins, with success [114–116].

In summary of this section, considerable progress has recently been made in the development of efficacious vaccines against *C. perfringens*-induced enteric diseases. The main issue that hampers a breakthrough in this field is the identification of a defined combination of antigens that is able to provide full protection against disease. These antigens will most likely target both the bacterial toxins and the bacterial colonization and proliferation. For the broiler industry, once the ideal vaccine antigens have been identified, development of an oral vaccine is needed.

3.2 Towards the development of new coccidiosis vaccines

Coccidiosis, an enteric disease cause by protozoan parasites of the genus *Eimeria*, remains a major economic and welfare concern for the poultry industry globally. Seven species (*Eimeria acervulina*, *E. brunetti*, *E. maxima*, *E. mitis*, *E. necatrix*, *E. praecox* and *E. tenella*) are known to infect chickens, and at least six others infect turkeys [117, 118]. The costs associated with coccidial disease are difficult to calculate, but have been estimated to exceed 3 billion US dollars for the chicken industry alone, worldwide [119]. Because coccidiosis is a predisposing factor for the occurrence of necrotic enteritis, the true economic burden is likely even higher. All *Eimeria* species can cause disease but the severity and clinical symptoms vary among species, and there is little or no cross-protection across species or some strains [120, 121].

3.2.1 Management of coccidiosis through anticoccidial drugs

Modern poultry production systems require effective control of coccidian parasites, typically through the routine use of anticoccidial drugs in feed or water. In the European Union, eleven different anticoccidial drugs are currently licensed and between 240 and 300 tonnes are sold for use in animals for markets such as the UK

every year [122]. Anticoccidial drugs can be divided into two groups, synthetic or chemical anticoccidials and ionophores, which are products of fermentation [123]. In some countries such as the US, ionophores are classified as antibiotics, albeit with low human medical importance.

The ionophores currently dominate the anticoccidial drug market, largely because they provide incomplete protection, even against naïve field strains without any drug resistance. Low levels of parasites survive and induce protective immunity against the prevailing local parasite strains, without causing clinical disease [124]. Anticoccidial drugs provide an efficient means of controlling coccidial parasites and are highly cost-effective. However, drug resistance is widespread and increasing consumer concerns related to drug use in livestock production and residues in the food chain encourage the use of alternatives such as vaccination. Notably, because coccidiosis is a predisposing factor for necrotic enteritis and other secondary bacterial infections, efficient control of this parasite is important to minimize the use of medically important antibiotics, including those deemed critically important for human health, in poultry production.

3.2.2 Traditional live anticoccidial vaccines

The first anticoccidial vaccine was marketed in 1952¹ [125]. It is a live parasite vaccine which includes multiple wild-type (i.e., non-attenuated) *Eimeria* species. Exposure to limited levels of such non-attenuated parasites permits the induction of a natural immune response in the chicken, resulting in protection against subsequent coccidial challenge. However, because protective immune responses against *Eimeria* are fully species specific, the inclusion of each individual target species is necessary if comprehensive protection is to be achieved, which results in relatively complex vaccine formulations. Such vaccines commonly include between three and eight parasite species or strains. The approach has been highly successful, although the lack of attenuation has been associated with reduced flock performance following vaccination and occasional clinical disease (reviewed elsewhere [126]).

In response to this limitation, a second generation of live *Eimeria* vaccines has been developed using attenuated parasite lines. For most of these vaccines, attenuation was achieved by selecting for so-called precocious strains, which typically exhibit reduced pathogenicity with fewer and/or smaller rounds of asexual replication. These attenuated strains retained their ability to immunize. The first live attenuated anticoccidial vaccine was

launched in 1989,² and several similar vaccines have been developed since using the same approach [126]. Non-attenuated and attenuated anticoccidial vaccines have become popular in the breeder and layer sectors, but are less widely used in the much larger broiler sector due to their relatively high cost compared to anticoccidial drugs and their limited availability. Because *Eimeria* cannot replicate effectively in vitro, the production of these live vaccines can only be achieved in *Eimeria*-free chickens and separate chickens have to be used for each species or strain to be included in a vaccine. Despite these production concerns billions of anticoccidial vaccine doses are sold every year, but more would be required to fully meet the growing demand.

3.2.3 Next generation anticoccidial vaccines

Efforts to improve on first and second generation live anticoccidial vaccines have included extensive attempts to identify antigens that are appropriate for use in sub-unit or recombinant vaccines. In addition, progress has been made on the preparation of novel adjuvants and some promising results have been obtained, although data on their use in poultry has so far remained fairly limited [127]. As an example, one vaccine³ is formulated from a crude mix of affinity purified *E. maxima* gametocyte antigens [128], although the levels of protection achieved have remained controversial and production of the vaccine still requires parasite amplification in chickens. Numerous studies have suggested that defined antigens such as apical membrane antigen 1, immune mapped protein 1, lactate dehydrogenase and SO7 are highly promising vaccine candidates (reviewed elsewhere [129]). Studies of *Eimeria* field populations have reported limited diversity in many of these antigens, indicating that recombinant vaccines for *Eimeria* may succeed even though antigenic diversity has undermined equivalent vaccines for related parasites such as *Plasmodium* [130, 131]. However, at present no recombinant anticoccidial vaccine is close to reaching the market.

One of the biggest remaining challenges is how to deliver the antigens in an affordable, effective, and, most importantly, scalable manner. A range of vectored expression/delivery systems have been suggested including Fowlpox virus (FWPV), HVT, *Salmonella* Typhimurium, yeasts such as *Saccharomyces cerevisiae* and the tobacco plant *Nicotiana tabacum*, with several showing promise [129]. Most recently, it has been suggested that *Eimeria* itself might function as an expression/delivery vector for vaccine antigens [132–134]. The ability to express

¹ Under the name Coccivac™.

² Under the name Paracox™.

³ Under the name CoxAbic™.

and deliver anticoccidial vaccine antigens from multiple parasite species in a single transgenic line could provide an opportunity to streamline anticoccidial vaccine production from as many as eight lines to just one or two. Using an attenuated vector species such as *E. acervulina* can improve productive capacity enormously and reduce vaccine cost. The parasite vector may also provide some ability as an adjuvant and methods for on-farm delivery are well established [133].

In summary of this section on new coccidiosis vaccines, as pressure to reduce antibiotic drug use in livestock production increases it is clear that the demand for coccidial vaccines is stronger than ever. In the US, approximately 35–40% of broiler companies use programs that include vaccination to control coccidiosis [135]. This trend is primarily driven by demands to produce “no antibiotics ever” poultry products. However, it has also been shown that some coccidial vaccines provide an opportunity to replace drug-resistant field parasites in a poultry house with susceptible vaccine strains. While current European attenuated vaccines are limited by their lower reproductive potential, live vaccines do retain considerable unexplored potential. A better understanding of the underlying immune mechanisms through which these nontraditional approaches operate is needed to allow further progress. Ultimately, it is clear that novel vaccines must be cost-effective, compatible with high standards of animal welfare, scalable and easy to deliver.

4 Autogenous vaccines to reduce the need for antibiotic use

Autogenous vaccines (AV) are also known as emergency, herd-specific or custom made vaccines. Although the legal basis and exact definition differs from country to country, AVs are used worldwide (e.g. EU, USA, Canada, Brazil, China, Indonesia, Australia, Egypt) and have a long history of use. The use of AVs for the control of fowl cholera has been well-documented [136, 137]. As a common definition, all AVs are made from inactivated bacterial or viral strains which were isolated from the same flock in which the vaccine is to be used. The use of AVs is only allowed if no licensed vaccine is available, or it is respectively ineffective or does not cover the current pathogen strains in the flock. The definition of a flock varies and may include integrated concepts of production chains in different places; to address the issue, the concept of an epidemiological link has recently been proposed by the Co-ordination Group for Mutual Recognition and Decentralised Procedures [138].

Licensed vaccines have advantages compared to AVs, including obligatory good manufacturing practice (GMP) production. Licensed vaccines are also produced in bigger batches with defined strains and a high level of

quality which makes their efficacy and safety predictable. However, licensed vaccines are not available in all cases.

To generate AVs, selected bacterial or viral strains are usually combined with a proper adjuvant. Several viral or bacterial species can be used in a combination vaccine and different serotypes can also be combined in a polyvalent vaccine. The combination of inactivated viruses and bacteria is also an option. Bacterial AVs are accepted in all countries of the economic European area, whereas viral AVs are not allowed in 10 European countries including France, Denmark and Spain [138].

A critical role in the successful production and use of an AV falls to the isolation of vaccine strains. Therefore diagnostic samples must be carefully obtained, based on appropriate choices regarding which sick and untreated animals to select for sample collection, which necropsy material to select, and which cultivation conditions and strains to use after results from sero-, toxo- or virulence-typing. For that purpose several methods like PCR, MALDI-TOF MS, slide agglutination or DNA sequencing are available. Because of the fundamental importance of the strain choice for the production of an adequate AV, close collaboration between diagnostic laboratory and vaccine production is critical. Each production is custom-made and numerous adjuvants, viral and bacterial isolates, including serotypes, toxins and species, provide countless combinations. This underlines the importance of experience as the basis in the production of high quality AVs. The veterinarian also has obligations regarding diagnosis, ordering and responsibility for the administration of the vaccine.

A variety of bacterial components are often used in AVs. These include for poultry: *Bordetella* spp., *Campylobacter* spp., *Cl. perfringens*, *Enterococcus cecorum*, *Erysipelothrix rhusiopathiae*, *E. coli*, *Gallibacterium anatis*, *Mycoplasma* spp., *Ornithobacterium rhinotracheale*, *Pasteurella multocida*, *Riemerella anatipestifer*; for swine: *Actinobacillus pleuropneumoniae*, *Bordetella* spp., *Brachyspira* spp., *Cl. perfringens*, *E. coli*, *H. parasuis*, *Mycoplasma* spp., *Pasteurella multocida*, *Strep. suis*, *Trueperella pyogenes*; for cattle: *Chlamydia* spp., *Cl. Perfringens*, *E. coli*, *Histophilus somni*, *Mannheimia haemolytica*, *Moraxella bovis*, *Mycoplasma* spp., *Pasteurella multocida*, *Salmonella enterica*, *Trueperella pyogenes*; and for fish: *Aeromonas* spp., *Photobacterium* spp., *Pseudomonas* spp., *Vibrio* spp., *Yersinia ruckeri*.

Depending on the animal species and age at vaccination different adjuvants can be used. As a standard adjuvant with good safety and efficacy, aluminium hydroxide is often used for production. Polymer and other gel-like adjuvants are also available for production in aqueous mixtures. Oily adjuvants, especially for water-in-oil emulsions, require a more sophisticated mixing procedure

because of the need of a stable emulsion. Furthermore oily vaccines might pose safety concerns. However, these induce a promising long lasting immune response because of a depot effect. In the case of organic animal production use of plant oil might be an option in order to avoid unwanted hydrocarbons. The risk of adverse effects, which depend on the adjuvant-antigen combination, can be decreased by standardization of the protocols.

More data regarding the efficacy and safety of AVs in field studies should be collected because clinical safety and efficacy is not regulated. The need for this is reflected by numerous current publications about viral and bacterial AVs for poultry [139–142], bovine [143], swine [144] and fish [145]. Most results show that AVs can be a useful alternative to antibiotic use.

Only a few countries allow the use of live AVs [138]. The normally inactivated vaccines must be tested for sterility. In the EU this could be carried out by internal tests according to the Pharmacopoeia [146]. Further steps in quality control include the inactivation test, endotoxin content or stability tests. Some producers offer GMP production, and GMP production is required in some countries such as Finland or Sweden [147]. In most countries GMP is only recommended. This example shows the vast differences in national legislation regarding the definition and interpretation of AVs. Because of worldwide circulation of animals and their pathogens a harmonization of manufacture, control and use of immunological veterinary medicinal products like AV is important, and the aim at the economic European area [138].

In summary, AVs are a valuable option in certain situations where commercial vaccines are either not available or expected to lack efficacy because of a mismatch between circulating and vaccine strains. The selection of adequate clinical isolates and vaccine formulations requires considerable expertise and the effective use of AVs depends on adequate manufacturing and appropriate veterinary oversight. Regulatory differences among countries create a highly fragmented legal landscape that would benefit from further harmonization.

5 Conclusions

Vaccines are proven strategies for the prevention or control of infectious diseases in animal populations. Therefore, they are promising alternatives that can reduce the need to use antibiotics in food-producing animals and their direct mitigating impact on antibiotic consumption has been demonstrated in a number of studies, even though the relationship between antibiotic use and vaccination is not in all cases clear-cut. The ideal vaccine is safe, effective against a broad range of pathogens, and easily adapted to mass-application. At the same time, it is cheap to produce and use, easy to register across key

jurisdictions, and generates durable protection, ideally after a single administration.

Existing vaccines still fall short of these ideals. In fact, many current vaccines have a number of shortcomings with regard to safety, efficacy and/or user-friendliness that limit their ability to replace antibiotic use. Overcoming these challenges will take close collaboration and innovative new approaches. Public–private partnerships represent one promising governing structure for assuring such close collaboration across public and private sectors. Investments in basic and applied research are equally needed to overcome these challenges, and research needs will have to be prioritized to ensure scarce resources will be preferentially dedicated to areas of greatest potential impact. Research to characterize and quantify the impact of vaccination on antibiotic use is equally needed.

Yet, some data demonstrating the ability of vaccines to reduce antibiotic consumption are already available. Similarly, key research breakthroughs and a number of highly promising vaccination approaches are already in development. These include new oral vaccines based on bacterial spores, live vectors, or new delivery strategies for inactivated oral vaccines; they also include new vaccination strategies in-ovo, combination vaccines that protect against multiple pathogens, the use of recent biotechnological advances, and comprehensive approaches to manage diseases caused by ubiquitous pathogens.

Therefore, further reductions in the need for antibiotic use through the use of new vaccines are all-but-certain, and investments in research and development of new vaccines will be vital for the sustained success of animal agricultural production around the world.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

KH, FVI, and CG planned the manuscript. KH led the drafting of the manuscript. LB, DPB, EC, SMC, BD, EEV, EG, KK, SL, MM, MR, MCS, NMW, CG, and FVI provided additional information and contributed to writing the manuscript including drafting selected sections and reviewing the manuscript. FVI and CG revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank the organizers, sponsors, and participants of the 2nd International Symposium on Alternatives to Antibiotics on which this manuscript is based, in particular the United States Department of Agriculture (USDA) and the World Organisation for Animal Health (OIE).

Author details

¹ The Pew Charitable Trusts, 901 E Street NW, Washington, DC 20004, USA.

² Ohio Agriculture and Research Development Center, Animal Sciences, Ohio State University, 202 Gerlaugh Hall, 1680 Madison Ave., Wooster, OH 44691, USA. ³ Pathobiology and Population Sciences, Royal Veterinary College, University of London, Hawkshead Lane, North Mymms, Hertfordshire AL9 7TA, UK.

⁴ Department of Virology, Parasitology and Immunology, Faculty of Veterinary Medicine, Ghent University, Salsiburylaan 133, 9820 Merelbeke, Belgium.

⁵ School of Biological Sciences, Royal Holloway University of London, Egham, Surrey TW20 0EX, UK. ⁶ Science and New Technologies Department, World Organisation for Animal Health (OIE), 12 Rue de Prony, 75017 Paris, France.

⁷ Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Salsburylaan 133, 9820 Merelbeke, Belgium.
⁸ Elanco Animal Health, 2500 Innovation Way, Greenfield, IN, USA. ⁹ Merial, 29 Avenue Tony Garnier, 69007 Lyon, France. ¹⁰ RIPAC-LABOR GmbH, Am Mühlberg 11, 14476 Potsdam, Germany. ¹¹ MSD, 2 Giralda Farms, Madison, NJ, USA.
¹² Office of National Programs, Agricultural Research Service, USDA, Sunnyside Ave, 5601 Beltsville, MD, USA.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 31 October 2017 Accepted: 22 December 2017

Published online: 31 July 2018

References

- Peterson LW, Artis D (2014) Intestinal epithelial cells: regulators of barrier function and immune homeostasis. *Nat Rev Immunol* 14:141–153
- Brandtzaeg P (2007) Induction of secretory immunity and memory at mucosal surfaces. *Vaccine* 25:5467–5484
- Plotkin SA (2009) Vaccines: the fourth century. *Clin Vaccine Immunol* 16:1709–1719
- Devriendt B, De Geest BG, Goddeeris BM, Cox E (2012) Crossing the barrier: targeting epithelial receptors for enhanced oral vaccine delivery. *J Control Release* 160:431–439
- Davitt CJH, Lavelle EC (2015) Delivery strategies to enhance oral vaccination against enteric infections. *Adv Drug Deliv Rev* 91:52–69
- Brandtzaeg P, Kiyono H, Pabst R, Russell MW (2008) Terminology: nomenclature of mucosa-associated lymphoid tissue. *Mucosal Immunol* 1:31–37
- Huyghebaert N, Snoeck V, Vermeire A, Cox E, Goddeeris BM, Remon JP (2005) Development of an enteric-coated pellet formulation of F4 fimbriae for oral vaccination of suckling piglets against enterotoxigenic *Escherichia coli* infections. *Eur J Pharm Biopharm* 59:273–281
- Schulz O, Pabst O (2013) Antigen sampling in the small intestine. *Trends Immunol* 34:155–161
- Ohno H (2015) Intestinal M cells. *J Biochem* 159:151–160
- Clark MA, Hirst BH, Jepson MA (1998) M-cell surface $\beta 1$ integrin expression and invasion-mediated targeting of *Yersinia pseudotuberculosis* to mouse Peyer's patch M cells. *Infect Immun* 66:1237–1243
- Hase K, Kawano K, Nochi T, Pontes GS, Fukuda S, Ebisawa M, Kadokura K, Tobe T, Fujimura Y, Kawano S, Yabashi A, Waguri S, Nakato G, Kimura S, Murakami T, Iimura M, Hamura K, Fukuoka S, Lowe AW, Itoh K, Kiyono H, Ohno H (2009) Uptake through glycoprotein 2 of FimH+ bacteria by M cells initiates mucosal immune response. *Nature* 462:226–230
- Mazzini E, Massimiliano L, Penna G, Rescigno M (2014) Oral tolerance can be established via gap junction transfer of fed antigens from CX3CR1+ macrophages to CD103+ dendritic cells. *Immunity* 40:248–261
- McDole JR, Wheeler LW, McDonald KG, Wang B, Konjufca V, Knoop KA, Newberry RD, Miller MJ (2012) Goblet cells deliver luminal antigen to CD103+ DCs in the small intestine. *Nature* 483:345–349
- Pridgen EM, Alexis F, Kuo TT, Levy-Nissenbaum E, Karnik R, Blumberg RS, Langer R, Farokhzad OC (2013) Transepithelial transport of Fc-targeted nanoparticles by the neonatal Fc receptor for oral delivery. *Sci Trans Med* 5:213ra167
- Melkebeek V, Goddeeris BM, Cox E (2013) ETEC vaccination in pigs. *Vet Immunol Immunopathol* 152:37–42
- Baert K, De Geest BG, De Rycke R, da Fonseca Antunes AB, De Greve H, Cox E, Devriendt B (2015) β -Glucan microparticles targeted to epithelial APN as oral antigen delivery system. *J Control Release* 220:149–159
- Iliev ID, Mileti E, Matteoli G, Chieppa M, Rescigno M (2009) Intestinal epithelial cells promote colitis-protective regulatory T-cell differentiation through dendritic cell conditioning. *Mucosal Immunol* 2:340–350
- Devriendt B, Stuyven E, Verdonck F, Goddeeris BM, Cox E (2010) Enterotoxigenic *Escherichia coli* (K88) induce proinflammatory responses in porcine intestinal epithelial cells. *Dev Comp Immunol* 34:1175–1182
- Norton EB, Branco LM, Clements JD (2015) Evaluating the A-subunit of the heat-labile toxin (LT) as an immunogen and a protective antigen against enterotoxigenic *Escherichia coli* (ETEC). *PLoS One* 10:e0136302
- Lundgren A, Jertborn M, Svennerholm A-M (2016) Induction of long term mucosal immunological memory in humans by an oral inactivated multivalent enterotoxigenic *Escherichia coli* vaccine. *Vaccine* 34:3132–3140
- Del Cacho E, Gallego M, Lee SH, Lillehoj HS, Quilez J, Lillehoj EP, Sánchez-Acedo C (2012) Induction of protective immunity against *Eimeria tenella*, *Eimeria maxima*, and *Eimeria acervulina* infections using dendritic cell-derived exosomes. *Infect Immun* 80:1909–1916
- Del Cacho E, Gallego M, Lillehoj HS, Quilez J, Lillehoj EP, Ramo A, Sánchez-Acedo C (2014) IL-17A regulates *Eimeria tenella* schizont maturation and migration in avian coccidiosis. *Vet Res* 45:25
- Kim WH, Jeong J, Park AR, Yim D, Kim Y-H, Kim KD, Chang HH, Lillehoj HS, Lee B-H, Min W (2012) Chicken IL-17F: identification and comparative expression analysis in *Eimeria*-infected chickens. *Dev Comp Immunol* 38:401–409
- Kim WH, Jeong J, Park AR, Yim D, Kim S, Chang HH, Yang S-H, Kim D-H, Lillehoj HS, Min W (2014) Downregulation of chicken interleukin-17 receptor A during *Eimeria* infection. *Infect Immun* 82:3845–3854
- Nicholson WL (2002) Roles of *Bacillus* endospores in the environment. *Cell Mol Life Sci* 59:410–416
- Nicholson WL, Munakata N, Horneck G, Melosh HJ, Setlow P (2000) Resistance of *Bacillus* endospores to extreme terrestrial and extraterrestrial environments. *Microbiol Mol Biol Rev* 64:548–572
- Hong HA, le Duc H, Cutting SM (2005) The use of bacterial spore formers as probiotics. *FEMS Microbiol Rev* 29:813–835
- Food and Agriculture Organization, World Health Organization (2002) Joint FAO/WHO (Food and Agriculture Organization/World Health Organization) working group report on drafting guidelines for the evaluation of probiotics in food. Food and Agriculture Organization, World Health Organization, London
- Hong HA, To E, Fakhry S, Baccigalupi L, Ricca E, Cutting SM (2009) Defining the natural habitat of *Bacillus* spore-formers. *Res Microbiol* 160:375–379
- Tam NK, Uyen NQ, Hong HA, le Duc H, Hoa TT, Serra CR, Henriques AO, Cutting SM (2006) The intestinal life cycle of *Bacillus subtilis* and close relatives. *J Bacteriol* 188:2692–2700
- Browne HP, Forster SC, Anonye BO, Kumar N, Neville BA, Stares MD, Goulding D, Lawley TD (2016) Culturing of 'unculturable' human microbiota reveals novel taxa and extensive sporulation. *Nature* 533:543–546
- Duc LH, Hong HA, Fairweather N, Ricca E, Cutting SM (2003) Bacterial spores as vaccine vehicles. *Infect Immun* 71:2810–2818
- Lee S, Belitsky BR, Brown DW, Brinker JP, Kerstein KO, Herrmann JE, Keusch GT, Sonenshein AL, Tzipori S (2010) Efficacy, heat stability and safety of intranasally administered *Bacillus subtilis* spore or vegetative cell vaccines expressing tetanus toxin fragment C. *Vaccine* 28:6658–6665
- Hoang TH, Hong HA, Clark GC, Titball RW, Cutting SM (2008) Recombinant *Bacillus subtilis* expressing the *Clostridium perfringens* alpha toxin is a candidate orally delivered vaccine against necrotic enteritis. *Infect Immun* 76:5257–5265
- Permpoonpattana P, Hong HA, Phetcharaburanin J, Huang JM, Cook J, Fairweather NF, Cutting SM (2011) Immunization with *Bacillus* spores expressing toxin A peptide repeats protects against infection with *Clostridium difficile* strains producing toxins A and B. *Infect Immun* 79:2295–2302
- Hong HA, Hitri K, Hosseini S, Kotowicz N, Bryan D, Mawar F, Wilkinson AJ, van Broekhoven A, Kearsy J, Cutting SM (2017) Mucosal antibodies to the C-terminus of toxin A prevent colonization of *Clostridium difficile*. *Infect Immun* 85:e01060–e01116
- Cutting SM (2013) CDVAX. European Union 7th Framework. <http://cdvax.org/>
- Huang JM, Hong HA, Van Tong H, Hoang TH, Brisson A, Cutting SM (2010) Mucosal delivery of antigens using adsorption to bacterial spores. *Vaccine* 28:1021–1030
- Song M, Hong HA, Huang JM, Colenutt C, Khang DD, Nguyen TV, Park SM, Shim BS, Song HH, Cheon IS, Jang JE, Choi JA, Choi YK, Stadler K, Cutting SM (2012) Killed *Bacillus subtilis* spores as a mucosal adjuvant for an H5N1 vaccine. *Vaccine* 30:3266–3277

40. Reljic R, Sibley L, Huang JM, Pepponi I, Hoppe A, Hong HA, Cutting SM (2013) Mucosal vaccination against tuberculosis using inert bioparticles. *Infect Immun* 81:4071–4080
41. Barnes AG, Cerovic V, Hobson PS, Klavinskis LS (2007) *Bacillus subtilis* spores: a novel microparticle adjuvant which can instruct a balanced Th1 and Th2 immune response to specific antigen. *Eur J Immunol* 37:1538–1547
42. Huang JM, La Ragione RM, Nunez A, Cutting SM (2008) Immunostimulatory activity of *Bacillus* spores. *FEMS Immunol Med Microbiol* 53:195–203
43. de Souza RD, Batista MT, Luiz WB, Cavalcante RC, Amorim JH, Bizerra RS, Martins EG, Ferreira LC (2014) *Bacillus subtilis* spores as vaccine adjuvants: further insights into the mechanisms of action. *PLoS One* 9:e87454
44. Amuguni JH, Lee S, Kerstein KO, Brown DW, Belitsky BR, Herrmann JE, Keusch GT, Sonenshein AL, Tzipori S (2011) Sublingually administered *Bacillus subtilis* cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice. *Vaccine* 29:4778–4784
45. Wang YG, Lee KL, Najiah M, Shariff M, Hassan MD (2000) A new bacterial white spot syndrome (BWSS) in cultured tiger shrimp *Penaeus monodon* and its comparison with white spot syndrome (WSS) caused by virus. *Dis Aquat Organ* 41:9–18
46. Pham KC, Tran HT, Van Doan C, Le PH, Van Nguyen AT, Nguyen HA, Hong HA, Cutting SM, Phan TN (2017) Protection of *Penaeus monodon* against white spot syndrome by continuous oral administration of a low concentration of *Bacillus subtilis* spores expressing the VP28 antigen. *Lett Appl Microbiol* 64:184–191
47. Valdez A, Yepiz-Plascencia G, Ricca E, Olmos J (2014) First *Litopenaeus vannamei* WSSV 100% oral vaccination protection using CotC:vp26 fusion protein displayed on *Bacillus subtilis* spores surface. *J Appl Microbiol* 117:347–357
48. Nguyen AT, Pham CK, Pham HT, Pham HL, Nguyen AH, Dang LT, Huynh HA, Cutting SM, Phan TN (2014) *Bacillus subtilis* spores expressing the VP28 antigen: a potential oral treatment to protect *Litopenaeus vannamei* against white spot syndrome. *FEMS Microbiol Lett* 358:202–208
49. Ning D, Leng X, Li Q, Xu W (2011) Surface-displayed VP28 on *Bacillus subtilis* spores induce protection against white spot syndrome virus in crayfish by oral administration. *J Appl Microbiol* 111:1327–1336
50. da Silva AJ, Zangirolami TC, Novo-Mansur MTM, Giordano RdC, Martins EAL (2014) Live bacterial vaccine vectors: an overview. *Braz J Microbiol* 45:1117–1129
51. Yang DM, Fairweather N, Button LL, McMaster WR, Kahl LP, Liew FY (1990) Oral *Salmonella typhimurium* (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. *J Immunol* 145:2281–2285
52. Tacket CO, Kelly SM, Schödel F, Losonsky G, Nataro JP, Edelman R, Levine MM, Curtiss R (1997) Safety and immunogenicity in humans of an attenuated *Salmonella typhi* vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. *Infect Immun* 65:3381–3385
53. Duc LH, Cutting SM (2003) Bacterial spores as heat stable vaccine vehicles. *Exp Opin Biol Ther* 3:1263–1270
54. Mauriello EMF, Duc LH, Isticato R, Cangiano G, Hong HA, De Felice M, Ricca E, Cutting SM (2004) Display of heterologous antigens on the *Bacillus subtilis* spore coat using CotC as a fusion partner. *Vaccine* 22:1177–1187
55. Arnold H, Bumann D, Felies M, Gewecke B, Sörensen M, Gessner JE, Freihost J, Von Specht BU, Baumann U (2004) Enhanced immunogenicity in the murine airway mucosa with an attenuated *Salmonella* live vaccine expressing OprF–OprI from *Pseudomonas aeruginosa*. *Infect Immun* 72:6546–6553
56. Zhang J, Shi Z, F-k Kong, Jex E, Huang Z, Watt JM, Van Kampen KR, De-chu CT (2006) Topical application of *Escherichia coli*-vectored vaccine as a simple method for eliciting protective immunity. *Infect Immun* 74:3607–3617
57. Kajikawa A, Satoh E, Leer RJ, Yamamoto S, Igimi S (2007) Intragastric immunization with recombinant *Lactobacillus casei* expressing flagellar antigen confers antibody-independent protective immunity against *Salmonella enterica* serovar Enteritidis. *Vaccine* 25:3599–3605
58. Wu C-M, Chung T-C (2007) Mice protected by oral immunization with *Lactobacillus reuteri* secreting fusion protein of *Escherichia coli* enterotoxin subunit protein. *FEMS Immunol Med Microbiol* 50:354–365
59. Deguchi K, Yokoyama E, Honda T, Mizuno K (2009) Efficacy of a novel trivalent inactivated vaccine against the shedding of *Salmonella* in a chicken challenge model. *Avian Dis* 53:281–286
60. Kim KS, Jenkins MC, Lillehoj HS (1989) Immunization of chickens with live *Escherichia coli* expressing *Eimeria acervulina* merozoite recombinant antigen induces partial protection against coccidiosis. *Infect Immun* 57:2434–2440
61. Ahmed B, Loos M, Vanrompay D, Cox E (2014) Oral immunization with *Lactococcus lactis*-expressing EspB induces protective immune responses against *Escherichia coli* O157: H7 in a murine model of colonization. *Vaccine* 32:3909–3916
62. Embregts CWE, Forlenza M (2016) Oral vaccination of fish: lessons from humans and veterinary species. *Dev Comp Immunol* 64:118–137
63. MacLachlan NJ, Dubovi EJ (2010) Fenner's veterinary virology. Academic press, Cambridge
64. Meeusen ENT, Walker J, Peters A, Pastoret P-P, Jungersen G (2007) Current status of veterinary vaccines. *Clin Microbiol Rev* 20:489–510
65. Ferreira TB, Alves PM, Aunins JG, Carrondo MJT (2005) Use of adenoviral vectors as veterinary vaccines. *Gene Ther* 12:573–83
66. Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AVS (2011) Viral vectors as vaccine platforms: deployment in sight. *Curr Opin Immunol* 23:377–382
67. Galen JE, Pasetti MF, Tennant S, Ruiz-Olvera P, Szein MB, Levine MM (2009) *Salmonella enterica* serovar Typhi live vector vaccines finally come of age. *Immunol Cell Biol* 87:400–412
68. Saxena M, Van TTH, Baird FJ, Coloe PJ, Smooker PM (2013) Pre-existing immunity against vaccine vectors—friend or foe? *Microbiology* 159:1–11
69. Hur J, Stein BD, Lee JH (2012) A vaccine candidate for post-weaning diarrhea in swine constructed with a live attenuated *Salmonella* delivering *Escherichia coli* K88ab, K88ac, FedA, and FedF fimbrial antigens and its immune responses in a murine model. *Can J Vet Res* 76:186–194
70. Stabel TJ, Mayfield JE, Morfitt DC, Wannemuehler MJ (1993) Oral immunization of mice and swine with an attenuated *Salmonella choleraesuis* [delta cya-12 delta(crp-cdt)19] mutant containing a recombinant plasmid. *Infect Immun* 61:610–618
71. Stabel TJ, Mayfield JE, Tabatabai LB, Wannemuehler MJ (1991) Swine immunity to an attenuated *Salmonella typhimurium* mutant containing a recombinant plasmid which codes for production of a 31-kDa protein of *Brucella abortus*. *Infect Immun* 59:2941–2947
72. Bielke LR, Wolfenden AD, Berghman LR, Kwon YM, Hargis BM (2016) Recombinant orally effective vaccine platforms expressing putative conserved antigens for reduced antimicrobial usage in poultry. In: Alternatives to antibiotics symposium, Paris, France, 2016. United States Department of Agriculture, Washington, D.C.
73. Briggs RE, Tatum FM (2016) Pasteurellaceae oral vaccine vector for economically important diseases of cattle. In: Alternatives to antibiotics symposium, Paris, France, 2016. United States Department of Agriculture, Washington, D.C.
74. Bal A (2011) In ovo vaccination for everyone. *Poultry World*. <http://www.poultryworld.net/Broilers/Health/2011/12/In-ovo-vaccination-for-everyone-WP009778W/>. Accessed 31 Aug 2017
75. Clements M (2012) Benefits of in ovo vaccination available to smaller hatcheries. WATTAgNet.com. <http://www.wattagnet.com/articles/12837-benefits-of-in-ovo-vaccination-available-to-smaller-hatcheries>. Accessed 31 Aug 2017
76. American College of Poultry Veterinarians (2011) From basics to field applications: poultry vaccination and immunity. In: American College of Poultry Veterinarians Workshop, Sacramento, California, 2011. American College of Poultry Veterinarians
77. Williams CJ, Hopkins BA (2011) Field evaluation of the accuracy of vaccine deposition by two different commercially available in ovo injection systems. *Poult Sci* 90:223–226
78. Negash T, Al-Garib SO, Gruys E (2004) Comparison of in ovo and post-hatch vaccination with particular reference to infectious bursal disease. A review. *Vet Q* 26:76–87
79. Fernandes JIM, Prokoski K, Oliveira BC, Oro CS, Oro PJ, Fernandes NLM (2016) Evaluation of incubation yield, vaccine response, and

- performance of broilers submitted to in-ovo vaccination at different embryonic ages. *Rev Bras Cienc Avic* 18:55–63
80. Ricks CA, Avakian A, Bryan T, Gildersleeve R, Haddad E, Ilich R, King S, Murray L, Phelps P, Poston R (1999) In ovo vaccination technology. *Adv Vet Med* 41:495–516
 81. Roh JH, Kang M, Wei B, Yoon RH, Seo HS, Bahng JY, Kwon JT, Cha SY, Jang HK (2016) Efficacy of HVT-IBD vector vaccine compared to attenuated live vaccine using in-ovo vaccination against a Korean very virulent IBDV in commercial broiler chickens. *Poult Sci* 95:1020–1024
 82. Jackwood DJ (2017) Advances in vaccine research against economically important viral diseases of food animals: infectious bursal disease virus. *Vet Microbiol* 206:121–125
 83. Gagic M, St. Hill CA, Sharma JM (1999) In ovo vaccination of specific-pathogen-free chickens with vaccines containing multiple agents. *Avian Dis* 43:293–301
 84. Lillehoj HS, Jang SI, Panebra A, Lillehoj EP, Dupuis L, Arous JB, Lee SK, Oh ST (2017) In ovo vaccination using *Eimeria* profilin and *Clostridium perfringens* NetB proteins in Montanide IMS adjuvant increases protective immunity against experimentally-induced necrotic enteritis. *Asian-Australasian J Anim Sci* 30:1478–1485
 85. Ge J, Wang X, Tian M, Wen Z, Feng Q, Qi X, Gao H, Wang X, Bu Z (2014) Novel in-ovo chimeric recombinant Newcastle disease vaccine protects against both Newcastle disease and infectious bursal disease. *Vaccine* 32:1514–1521
 86. Toro H, De-chu CT, Suarez DL, Sylte MJ, Pfeiffer J, Van Kampen KR (2007) Protective avian influenza in ovo vaccination with non-replicating human adenovirus vector. *Vaccine* 25:2886–2891
 87. Johnson DI, Vagnozzi A, Dorea F, Riblet SM, Mundt A, Zavala G, García M (2010) Protection against infectious laryngotracheitis by in ovo vaccination with commercially available viral vector recombinant vaccines. *Avian Dis* 54:1251–1259
 88. Ding X, Lillehoj HS, Dalloul RA, Min W, Sato T, Yasuda A, Lillehoj EP (2005) In ovo vaccination with the *Eimeria tenella* EtMIC2 gene induces protective immunity against coccidiosis. *Vaccine* 23:3733–3740
 89. Sokale AO, Zhai W, Pote LM, Williams CJ, Peebles ED (2016) Effects of coccidiosis vaccination administered by in ovo injection on the hatchability and hatching chick quality of broilers 1, 2, 3. *Poult Sci* 96:541–547
 90. Sarfraz M, Suleman M, Tikoo SK, Wheler C, Potter AA, Gerdtz V, Dar A (2017) Immune responses to in ovo vaccine formulations containing inactivated fowl adenovirus 8b with poly [di (sodium carboxylatoethyl-phenoxyl)] phosphazene (PCEP) and avian beta defensin as adjuvants in chickens. *Vaccine* 35:981–986
 91. Elliott KEC, Branton SL, Evans JD, Gerard PD, Peebles ED (2017) Layer chicken embryo survival to hatch when administered an in ovo vaccination of strain F Mycoplasma gallisepticum and locations of bacteria prevalence in the newly hatched chick 1, 2, 3. *Poult Sci* 96:3879–3884
 92. Songer JG (1996) Clostridial enteric diseases of domestic animals. *Clin Microbiol Rev* 9:216–234
 93. Petit L, Gilbert M, Popoff MR (1999) *Clostridium perfringens*: toxinotype and genotype. *Trends Microbiol* 7:104–110
 94. Songer JG, Uzal FA (2005) Clostridial enteric infections in pigs. *J Vet Diagn Invest* 17:528–536
 95. Uzal FA, McClane BA (2011) Recent progress in understanding the pathogenesis of *Clostridium perfringens* type C infections. *Vet Microbiol* 153:37–43
 96. Uzal FA, Vidal JE, McClane BA, Gurjar AA (2010) *Clostridium perfringens* toxins involved in mammalian veterinary diseases. *Open Toxinol J* 2:24–42
 97. Mot D, Timbermont L, Delezie E, Haesebrouck F, Ducatelle R, Van Immerseel F (2013) Day-of-hatch vaccination is not protective against necrotic enteritis in broiler chickens. *Avian Pathol* 42:179–184
 98. Friedman A (2008) Oral tolerance in birds and mammals: digestive tract development determines the strategy. *J Appl Poult Res* 17:168–173
 99. Rappuoli R, Black S, Lambert PH (2011) Vaccine discovery and translation of new vaccine technology. *Lancet* 378:360–368
 100. Kulkarni RR, Parreira VR, Sharif S, Prescott JF (2008) Oral immunization of broiler chickens against necrotic enteritis with an attenuated *Salmonella* vaccine vector expressing *Clostridium perfringens* antigens. *Vaccine* 26:4194–4203
 101. Kulkarni RR, Parreira VR, Jiang YF, Prescott JF (2010) A live oral recombinant *Salmonella enterica* serovar typhimurium vaccine expressing *Clostridium perfringens* antigens confers protection against necrotic enteritis in broiler chickens. *Clin Vaccine Immunol* 17:205–214
 102. Zekarias B, Mo H, Curtiss R 3rd (2008) Recombinant attenuated *Salmonella enterica* serovar typhimurium expressing the carboxy-terminal domain of alpha toxin from *Clostridium perfringens* induces protective responses against necrotic enteritis in chickens. *Clin Vaccine Immunol* 15:805–816
 103. Jiang Y, Kulkarni RR, Parreira VR, Poppe C, Roland KL, Prescott JF (2010) Assessment of 2 *Salmonella enterica* serovar typhimurium-based vaccines against necrotic enteritis in reducing colonization of chickens by *Salmonella* serovars of different serogroups. *Can J Vet Res* 74:264–270
 104. Alimolaei M, Golchin M, Daneshvar H (2016) Oral immunization of mice against *Clostridium perfringens* epsilon toxin with a *Lactobacillus casei* vector vaccine expressing epsilon toxoid. *Infect Genet Evol* 40:282–287
 105. Lanckriet A, Timbermont L, Eeckhaut V, Haesebrouck F, Ducatelle R, Van Immerseel F (2010) Variable protection after vaccination of broiler chickens against necrotic enteritis using supernatants of different *Clostridium perfringens* strains. *Vaccine* 28:5920–5923
 106. Mot D, Timbermont L, Haesebrouck F, Ducatelle R, Van Immerseel F (2014) Progress and problems in vaccination against necrotic enteritis in broiler chickens. *Avian Pathol* 43:290–300
 107. Jiang Y, Mo H, Willingham C, Wang S, Park JY, Kong W, Roland KL, Curtiss R 3rd (2015) Protection against necrotic enteritis in broiler chickens by regulated delayed lysis *Salmonella* vaccines. *Avian Dis* 59:475–485
 108. Fernandes da Costa SP, Mot D, Geeraerts S, Bokori-Brown M, Immerseel FV, Titball RW (2016) Variable protection against experimental broiler necrotic enteritis after immunisation with the C-terminal fragment of *Clostridium perfringens* alpha-toxin and a non-toxic NetB variant. *Avian Pathol* 45:381–388
 109. Wade B, Keyburn AL, Haring V, Ford M, Rood JI, Moore RJ (2016) The adherent abilities of *Clostridium perfringens* strains are critical for the pathogenesis of avian necrotic enteritis. *Vet Microbiol* 197:53–61
 110. Goossens E, Valgaeren BR, Pardon B, Haesebrouck F, Ducatelle R, Deprez PR, Van Immerseel F (2017) Rethinking the role of alpha toxin in *Clostridium perfringens*-associated enteric diseases: a review on bovine necro-haemorrhagic enteritis. *Vet Res* 48:9
 111. Goossens E, Verherstraeten S, Valgaeren BR, Pardon B, Timbermont L, Schauvliege S, Rodrigo-Mocholi D, Haesebrouck F, Ducatelle R, Deprez PR, Van Immerseel F (2016) The C-terminal domain of *Clostridium perfringens* alpha toxin as a vaccine candidate against bovine necrohemorrhagic enteritis. *Vet Res* 47:52
 112. Goossens E, Verherstraeten S, Valgaeren BR, Pardon B, Timbermont L, Schauvliege S, Rodrigo-Mocholi D, Haesebrouck F, Ducatelle R, Deprez PR, Van Immerseel F (2016) Toxin-neutralizing antibodies protect against *Clostridium perfringens*-induced necrosis in an intestinal loop model for bovine necrohemorrhagic enteritis. *BMC Vet Res* 12:101
 113. Ferreira MR, Moreira GM, Cunha CE, Mendonca M, Salvarani FM, Moreira AN, Conceicao FR (2016) Recombinant alpha, beta, and epsilon toxins of *Clostridium perfringens*: production strategies and applications as veterinary vaccines. *Toxins* 8:E340
 114. Lobato FC, Lima CG, Assis RA, Pires PS, Silva RO, Salvarani FM, Carmo AO, Contigli C, Kalapothakis E (2010) Potency against enterotoxemia of a recombinant *Clostridium perfringens* type D epsilon toxoid in ruminants. *Vaccine* 28:6125–6127
 115. Zeng J, Deng G, Wang J, Zhou J, Liu X, Xie Q, Wang Y (2011) Potential protective immunogenicity of recombinant *Clostridium perfringens* alpha-beta2-beta1 fusion toxin in mice, sows and cows. *Vaccine* 29:5459–5466
 116. Moreira C Jr, da Cunha CE, Moreira GM, Mendonca M, Salvarani FM, Moreira AN, Conceicao FR (2016) Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D. *Anaerobe* 40:58–62
 117. Vrba V, Pakandl M (2015) Host specificity of turkey and chicken *Eimeria*: controlled cross-transmission studies and a phylogenetic view. *Vet Parasitol* 208:118–124
 118. Clark EL, Macdonald SE, Thenmozhi V, Kundu K, Garg R, Kumar S, Ayoade S, Fornace KM, Jatau ID, Mofteh A, Nolan MJ, Sudhakar NR, Adebambo AO, Lawal IA, Alvarez Zapata R, Awuni JA, Chapman HD, Karimuribo E, Mugasa CM, Namangala B, Rushton J, Suo X, Thangaraj K, Srinivasa Rao AS, Tewari AK, Banerjee PS, Dhinakar Raj G, Raman M, Tomley FM, Blake DP (2016) Cryptic *Eimeria* genotypes are common

- across the southern but not northern hemisphere. *Int J Parasitol* 46:537–544
119. Dalloul RA, Lillehoj HS (2006) Poultry coccidiosis: recent advancements in control measures and vaccine development. *Exp Rev Vaccines* 5:143–163
 120. Long P, Joyner L, Millard B, Norton C (1976) A guide to laboratory techniques used in the study and diagnosis of avian coccidiosis. *Folia Vet Lat* 6:201–217
 121. Williams RB, Marshall RN, Pages M, Dardi M, del Cacho E (2009) Pathogenesis of *Eimeria praecox* in chickens: virulence of field strains compared with laboratory strains of *E. praecox* and *Eimeria acervulina*. *Avian Pathol* 38:359–366
 122. Eckford S, Grace K, Harris C, Reeves H, Teale C, Tallentire C (2014) UK-VARSS 2013. UK Veterinary Antibiotic Resistance and Sales Surveillance Report
 123. Chapman H (1997) Biochemical, genetic and applied aspects of drug resistance in *Eimeria* parasites of the fowl. *Avian Pathol* 26:221–244
 124. Chapman HD (1999) Anticoccidial drugs and their effects upon the development of immunity to *Eimeria* infections in poultry. *Avian Pathol* 28:521–535
 125. Williams RB (2002) Fifty years of anticoccidial vaccines for poultry (1952–2002). *Avian Dis* 46:775–802
 126. Shirley MW, Smith AL, Tomley FM (2005) The biology of avian *Eimeria* with an emphasis on their control by vaccination. *Adv Parasitol* 60:285–330
 127. Jang SI, Lillehoj HS, Lee SH, Lee KW, Lillehoj EP, Bertrand F, Dupuis L, Deville S (2011) Montanide™ ISA 71 VG adjuvant enhances antibody and cell-mediated immune responses to profilin subunit antigen vaccination and promotes protection against *Eimeria acervulina* and *Eimeria tenella*. *Exp Parasitol* 127:178–183
 128. Wallach M (2010) Role of antibody in immunity and control of chicken coccidiosis. *Trends Parasitol* 26:382–387
 129. Blake DP, Tomley FM (2014) Securing poultry production from the ever-present *Eimeria* challenge. *Trends Parasitol* 30:12–19
 130. Kundu K, Garg R, Kumar S, Mandal M, Tomley F, Blake D, Banerjee P (2017) Humoral and cytokine response elicited during immunisation with recombinant immune mapped protein-1 (EtIMP-1) and oocysts of *Eimeria tenella*. *Vet Parasitol* 244:44–53
 131. Blake DP, Clark EL, Macdonald SE, Thenmozhi V, Kundu K, Garg R, Jatau ID, Ayoade S, Kawahara F, Moftah A, Reid AJ, Adebambo AO, Alvarez Zapata R, Srinivasa Rao AS, Thangaraj K, Banerjee PS, Dhinakar-Raj G, Raman M, Tomley FM (2015) Population, genetic, and antigenic diversity of the apicomplexan *Eimeria tenella* and their relevance to vaccine development. *Proc Natl Acad Sci U S A* 112:E5343–5350
 132. Clark JD, Oakes RD, Redhead K, Crouch CF, Francis MJ, Tomley FM, Blake DP (2012) *Eimeria* species parasites as novel vaccine delivery vectors: anti-*Campylobacter jejuni* protective immunity induced by *Eimeria tenella*-delivered CjaA. *Vaccine* 30:2683–2688
 133. Marugan-Hernandez V, Cockle C, Macdonald S, Pegg E, Crouch C, Blake DP, Tomley FM (2016) Viral proteins expressed in the protozoan parasite *Eimeria tenella* are detected by the chicken immune system. *Parasit Vectors* 9:463
 134. Huang X, Zou J, Xu H, Ding Y, Yin G, Liu X, Suo X (2011) Transgenic *Eimeria tenella* expressing enhanced yellow fluorescent protein targeted to different cellular compartments stimulated dichotomic immune responses in chickens. *J Immunol* 187:3595–3602
 135. Chapman HD, Jeffers TK (2014) Vaccination of chickens against coccidiosis ameliorates drug resistance in commercial poultry production. *Int J Parasitol Drugs Drug Resist* 4:214–217
 136. Queen FB, Quortrup ER (1946) Treatment of *Pasteurella multocida* (fowl cholera) infection in wild ducks with autogenous bacterin and penicillin. *J Am Vet Med Assoc* 108:101–103
 137. Olson LD, McCune EL, Bond RE (1969) Comparison of commercial and autogenous bacterins for control of the cranial form of fowl cholera in turkeys. *Avian Dis* 13:252–260
 138. CMDv (2017) Recommendations for the manufacture, control and use of inactivated autogenous veterinary vaccines within the EEA. European Medicines Agency Co-ordination Group for Mutual Recognition and Decentralised Procedures—Veterinary, London
 139. Jung A, Metzner M, Köhler-Repp D, Rautenschlein S (2013) Experimental reproduction of an *Enterococcus cecorum* infection in Pekin ducks. *Avian Pathol* 42:552–556
 140. Gharaibeh S, Amareen S (2015) Vaccine efficacy against a new avian influenza (H9N2) field isolate from the Middle East (serology and challenge studies). *Avian Dis* 59:508–511
 141. Groves PJ, Sharpe SM, Muir WI, Pavic A, Cox JM (2016) Live and inactivated vaccine regimens against caecal *Salmonella typhimurium* colonisation in laying hens. *Aust Vet J* 94:387–393
 142. Li L, Thøfner I, Christensen JP, Ronco T, Pedersen K, Olsen RH (2017) Evaluation of the efficacy of an autogenous *Escherichia coli* vaccine in broiler breeders. *Avian Pathol* 46:300–308
 143. Dudek K, Bednarek D, Ayling RD, Kycko A, Szacawa E, Karpińska TA (2016) An experimental vaccine composed of two adjuvants gives protection against *Mycoplasma bovis* in calves. *Vaccine* 34:3051–3058
 144. Geldhof MF, Van Breedam W, De Jong E, Rodriguez AL, Karniyuchuk UU, Vanhee M, Van Doorselaere J, Maes D, Nauwynck HJ (2013) Antibody response and maternal immunity upon boosting PRRSV-immune sows with experimental farm-specific and commercial PRRSV vaccines. *Vet Microbiol* 167:260–271
 145. Fukushima HCS, Leal CAG, Cavalcante RB, Figueiredo HCP, Arijó S, Moriñigo MA, Ishikawa M, Borra RC, Ranzani-Paiva MJT (2017) *Lactococcus garvieae* outbreaks in Brazilian farms *Lactococcus* in *Pseudoplattystoma* sp.—development of an autogenous vaccine as a control strategy. *J Fish Dis* 40:263–272
 146. British Pharmacopoeia (2016) British pharmacopoeia. Her Majesty Stationery Office, London
 147. Attia Y, Schmerold I, Hönel A (2013) The legal foundation of the production and use of herd-specific vaccines in Europe. *Vaccine* 31:3651–3655

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

